Overview

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function. The study will also evaluate safety and tolerability in subjects with hepatic impairment.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca